EADV24: Novo’s semaglutide shows potential in chronic skin condition in obese patients - Endpoints News

A small study conducted by researchers at St. Vincent's University Hospital in Dublin suggests that Novo Nordisk's GLP-1 semaglutide could treat a common and chronic skin condition called hidradenitis suppurativa. The study, published Wednesday at the Eur